Imaging in Type 1 Diabetes, Current Perspectives and Directions.
Autor: | Tinklepaugh J; Research Department, JDRF, 200 Vesey Street, New York, NY, USA., Mamrak NE; Research Department, JDRF, 200 Vesey Street, New York, NY, USA. NMamrak@jdrf.org. |
---|---|
Jazyk: | angličtina |
Zdroj: | Molecular imaging and biology [Mol Imaging Biol] 2023 Dec; Vol. 25 (6), pp. 1142-1149. Date of Electronic Publication: 2023 Nov 07. |
DOI: | 10.1007/s11307-023-01873-y |
Abstrakt: | Type 1 diabetes (T1D) is characterized by the autoimmune-mediated attack of insulin-producing beta cells in the pancreas, leading to reliance on exogenous insulin to control a patient's blood glucose levels. As progress is being made in understanding the pathophysiology of the disease and how to better develop therapies to treat it, there is an increasing need for monitoring technologies to quantify beta cell mass and function throughout T1D progression and beta cell replacement therapy. Molecular imaging techniques offer a possible solution through both radiologic and non-radiologic means including positron emission tomography, magnetic resonance imaging, electron paramagnetic resonance imaging, and spatial omics. This commentary piece outlines the role of molecular imaging in T1D research and highlights the need for further applications of such methodologies in T1D. (© 2023. The Author(s), under exclusive licence to World Molecular Imaging Society.) |
Databáze: | MEDLINE |
Externí odkaz: |